In vivo activity of a novel polymeric guanidine in experimental skin infection with methicillin-resistant Staphylococcus aureus.
The in vivo efficacy of the novel polymeric guanidine AKACID Plus was evaluated in a guinea pig model of experimental skin infection with methicillin-resistant Staphylococcus aureus (MRSA). Topical application of AKACID Plus at concentrations of > or =0.5% was as effective as mupirocin 2% cream in the treatment of superficial skin infection with MRSA.
Kratzer
Christina
C
Department of Internal Medicine I, Division of Infectious Diseases and Chemotherapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Tobudic
Selma
S
Macfelda
Karin
K
Graninger
Wolfgang
W
Georgopoulos
Apostolos
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004305:Dose-Response Relationship, Drug; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006168:Guinea Pigs; D008297:Male; D016106:Methicillin Resistance; D016712:Mupirocin / Q000494:pharmacology; D011108:Polymers / Q000627:therapeutic use*; D012867:Skin / Q000382:microbiology; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology
C512857:AKACID Plus; D000900:Anti-Bacterial Agents; D006146:Guanidines; D011108:Polymers; D016712:Mupirocin